Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Osteoporos Int. 2022 Sep;33(9):1957-1967. doi: 10.1007/s00198-022-06425-8. Epub 2022 May 18.
The widely recommended fracture prediction tool FRAX was developed based on and for the general population. Although several adjusted FRAX methods were suggested for type 2 diabetes (T2DM), they still need to be evaluated in T2DM cohort.
This study was undertaken to develop a prediction model for Chinese diabetes fracture risk (CDFR) and compare its performance with those of FRAX.
In this retrospective cohort study, 1730 patients with T2DM were enrolled from 2009.08 to 2013.07. Major osteoporotic fractures (MOFs) during follow-up were collected from Electronic Health Records (EHRs) and telephone interviews. Multivariate Cox regression with backward stepwise selection was used to fit the model. The performances of the CDFR model, FRAX, and adjusted FRAX were compared in the aspects of discrimination and calibration.
6.3% of participants experienced MOF during a median follow-up of 10 years. The final model (CDFR) included 8 predictors: age, gender, previous fracture, insulin use, diabetic peripheral neuropathy (DPN), total cholesterol, triglycerides, and apolipoprotein A. This model had a C statistic of 0.803 (95%CI 0.761-0.844) and calibration χ of 4.63 (p = 0.86). The unadjusted FRAX underestimated the MOF risk (calibration χ 134.5, p < 0.001; observed/predicted ratio 2.62, 95%CI 2.17-3.08), and there was still significant underestimation after diabetes adjustments. Comparing FRAX, the CDFR had a higher AUC, lower calibration χ, and better reclassification of MOF.
The CDFR model has good performance in 10-year MOF risk prediction in T2DM, especially in patients with insulin use or DPN. Future work is needed to validate our model in external cohort(s).
FRAX 是一种广泛推荐的骨折预测工具,它是基于一般人群开发的。虽然已经提出了几种针对 2 型糖尿病(T2DM)的调整后的 FRAX 方法,但仍需要在 T2DM 队列中进行评估。
在这项回顾性队列研究中,纳入了 2009 年 8 月至 2013 年 7 月期间的 1730 名 T2DM 患者。通过电子健康记录(EHR)和电话访谈收集随访期间的主要骨质疏松性骨折(MOF)。使用向后逐步选择的多变量 Cox 回归来拟合模型。在区分度和校准方面比较了 CDFR 模型、FRAX 和调整后的 FRAX 的性能。
在中位随访 10 年期间,有 6.3%的参与者发生 MOF。最终模型(CDFR)包含 8 个预测因素:年龄、性别、既往骨折、胰岛素使用、糖尿病周围神经病变(DPN)、总胆固醇、甘油三酯和载脂蛋白 A。该模型的 C 统计量为 0.803(95%CI 0.761-0.844),校准 χ 为 4.63(p=0.86)。未调整的 FRAX 低估了 MOF 风险(校准 χ 134.5,p<0.001;观察值/预测值比为 2.62,95%CI 2.17-3.08),并且在糖尿病调整后仍然存在显著低估。与 FRAX 相比,CDFR 的 AUC 更高,校准 χ 更低,对 MOF 的重新分类更好。
CDFR 模型在 T2DM 中具有良好的 10 年 MOF 风险预测性能,尤其是在使用胰岛素或 DPN 的患者中。需要进一步的工作来验证我们的模型在外部队列中的效果。